R&D at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s R&D?
- Trevi Therapeutics, Inc. (TRVI) reported R&D of $9.94M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s R&D changed year-over-year?
- Trevi Therapeutics, Inc.'s R&D increased by 27.3% year-over-year, from $7.81M to $9.94M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s R&D has grown at a 9.9% compound annual growth rate (CAGR), from $22.98M to $33.48M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.